Inquiry Basket
Loading ......
Filter By Product Search for
TP53
TP53 Full Name
tumor protein p53
TP53 Introduction
TP53, which encodes the tumor suppressor protein p53, is one of the most intensively studied genes in modern cancer biology because of its central role in protecting genomic stability and preventing malignant transformation. Located on chromosome 17p13.1, TP53 encodes a transcription factor that responds to cellular stress signals such as DNA damage, oxidative stress, hypoxia, oncogene activation, and radiation exposure. Researchers and clinicians often refer to p53 as the "guardian of the genome" because it helps determine whether damaged cells should pause the cell cycle for repair, enter senescence, or undergo apoptosis. For scientists developing oncology therapies or diagnostic platforms, TP53 remains a critical biomarker due to its exceptionally high mutation frequency across human cancers. Structurally, the p53 protein contains several functional domains, including transactivation domains, a proline-rich region, a DNA-binding domain, a tetramerization domain, and a C-terminal regulatory region, all of which coordinate complex transcriptional programs that influence cell fate. Importantly, alternative promoters and splice variants such as p53β and p53γ contribute to tissue-specific responses and biological diversity, helping explain why tumors from different organs may respond differently to hypoxia, chemotherapy, or radiation stress.
The biological function of TP53 extends far beyond classical tumor suppression, making it highly relevant for translational medicine, drug discovery, and precision oncology research. Under normal physiological conditions, p53 activity is tightly controlled by MDM2, an E3 ubiquitin ligase that promotes p53 degradation and maintains low intracellular p53 levels. Following genotoxic or oncogenic stress, post-translational modifications including phosphorylation and acetylation stabilize p53 and activate downstream transcriptional networks involved in DNA repair, metabolic regulation, ferroptosis, autophagy, senescence, and apoptosis. A major challenge in cancer therapeutics is that TP53 mutations are not simply loss-of-function events. Many hotspot mutations located within the DNA-binding domain, such as R175H, R248Q, R273H, and R282W, can produce gain-of-function mutant p53 proteins that actively drive tumor progression, metastasis, immune evasion, and resistance to chemotherapy. These mutant proteins may interfere with tumor suppressors including p63 and p73 or cooperate with oncogenic transcription factors to promote aggressive cancer phenotypes. As a result, researchers searching for more durable anti-cancer strategies are increasingly focused on mutant p53 reactivation, synthetic lethality approaches, MDM2 inhibitors, and next-generation gene editing technologies targeting the TP53 pathway.
TP53 abnormalities are strongly associated with a broad spectrum of human diseases, especially solid tumors and hereditary cancer syndromes, making this target highly valuable in both clinical diagnostics and therapeutic development. Mutations in TP53 are detected in a large proportion of ovarian cancer, lung cancer, colorectal cancer, breast cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and head and neck cancers, where they often correlate with poor prognosis, tumor recurrence, and treatment resistance. Germline TP53 mutations are also the defining molecular feature of Li-Fraumeni syndrome, a rare hereditary disorder characterized by early-onset and multiple primary cancers across a patient's lifetime. In esophageal squamous cell carcinoma, TP53 mutations are closely linked to environmental and lifestyle risk factors such as smoking and alcohol consumption, highlighting the interaction between carcinogen exposure and genomic instability. Clinically, TP53 mutation profiling using next-generation sequencing and immunohistochemistry has become increasingly important for patient stratification, prognosis assessment, and targeted therapy selection. Although significant progress has been made in understanding TP53 signaling networks, translating this knowledge into consistently effective therapies remains challenging because of the pathway's complexity, mutation heterogeneity, and context-dependent biological behavior. Nevertheless, TP53 continues to be one of the most promising and clinically actionable molecular targets in oncology research, particularly for researchers seeking innovative approaches to overcome drug resistance and improve long-term cancer outcomes.
Alternate Names for TP53
TP53; tumor protein p53; P53; BCC7; LFS1; TRP53; cellular tumor antigen p53; antigen NY-CO-13; tumor protein 53; phosphoprotein p53; p53 tumor suppressor; mutant tumor protein 53; transformation-related protein 53;
Loading ......
